Driven by Biopharma 4.0, proteomics research
and acquisition of TRACE Analytics, 908 Devices empowers more
effective drug discoveries
908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld
and desktop mass spec devices for chemical and biomolecular
analysis, continues to equip its life science customers with
actionable intelligence at the point-of-need, enabling them to
drive advancements in biotherapeutic development.
“Through both our REBEL and ZipChip devices, we’re empowering
researchers and process engineers with rapid and robust analytics
at the push of a button,” said Kevin J. Knopp, CEO and co-founder
of 908 Devices. “By providing our users with real-time control of
critical product and process attributes, 908 Devices is empowering
dramatic efficiencies throughout the drug development
lifecycle.”
The organization’s commitment to accelerating biotherapeutic
workflows is evidenced through its collaborations with key industry
partners and leading academic institutions, which were demonstrated
through the following events and presentations over the past six
months, including:
CE-Pharm and CASSS-Mass Spec
908 Devices collaborated with CPI,
Bio-Techne, ProtaGene, Thermo Fisher Scientific and Protein
Metrics, and technical posters summarizing these efforts were
shared at recent industry conferences. A poster from CPI
highlighted the value of at-line cell culture media analysis to
inform feeding strategies for improved cell growth. CPI process
engineers used real-time data from REBEL to optimize cell
nutrients, resulting in an increase in titer by up to 40% and a
reduction in toxic metabolite accumulation. Posters with other
collaborators highlighted ZipChip’s benefits of sensitivity and
resolution, with minimal sample volumes in peptide mapping and
charge variant analysis, and the benefit of no harsh ion-pairing
reagents when characterizing oligonucleotides.
BioProcess International, part of Boston
Biotech Week
There were two notable moments from the
event; the first of which included a presentation by a Johns
Hopkins University researcher about harnessing REBEL’s power for
at-line amino acid monitoring to enable complex bioprocessing
modeling. The second included a presentation by a Symphogen
scientist about mass spec-based characterization workflows in
biopharmaceutical labs that noted ZipChip’s efficiencies in
performing high resolution separations and minimizing sample prep
burdens.
ASMS
At the 70th American Society for Mass
Spectrometry (ASMS) conference, 908 Devices and its customers
presented one oral session and eleven posters, highlighting the use
of ZipChip or REBEL to accelerate drug development workflows.
Collaborators included Genentech, University of Washington, Fudan
University and Dana-Farber Cancer Institute. In addition, 908
Devices presented an update on its microfluidic prototype chip
developments that accommodate larger sample volumes and increases
in speed and sensitivity, targeted for proteomics applications.
908 Devices Critical Mass User Meeting
908 Devices gathered 175 users, in person and
virtual, to share insights and successes using its devices.
Scientists from Boehringer Ingelheim touted ZipChip’s very fast
separations and high sensitivity in characterizing product quality
attributes in oligonucleotides and monoclonal antibodies while MIT
and Clemson researchers demonstrated REBEL’s value in their ability
to rapidly monitor and profile nutrient consumption of recombinant
AAV producing cells.
Robust on-line data and support for customers
Beyond these scientific advancements and successes in the life
sciences industry, in order to better serve its customers, 908
Devices acquired TRACE Analytics, which specializes in on-line
aseptic sampling systems and novel biosensors for bioreactor
monitoring and control. This technology will further the company’s
goal to build a connected and comprehensive bioanalytics platform,
a key enabler of Biopharma 4.0.
“Through all these efforts, we’re seeking to revolutionize how
chemical and biochemical analysis is being conducted, and our
customers are able to quickly, confidently and more easily
understand the lifecycle of their drug development,” said Kevin J.
Knopp.
For more information about 908 Devices’ life sciences
capabilities, please visit www.908devices.com.
About 908 Devices
908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass
spectrometry with its simple handheld and desktop devices,
addressing critical-to-life applications. The Company’s devices are
used at the point-of-need to interrogate unknown and invisible
materials and provide quick, actionable answers to directly address
some of the most critical problems in life sciences research,
bioprocessing, pharma / biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic separations, software
automation and machine learning.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221110005340/en/
Media Barbara Russo brusso@908devices.com
Investor Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
過去 株価チャート
から 6 2024 まで 7 2024
908 Devices (NASDAQ:MASS)
過去 株価チャート
から 7 2023 まで 7 2024